NCT03863132 (REBOOT-PARADOX) is a NA clinical trial of TAVR in Aortic Valve Stenosis, sponsored by IHF GmbH - Institut für Herzinfarktforschung.

Who is sponsoring NCT03863132?

NCT03863132 is sponsored by IHF GmbH - Institut für Herzinfarktforschung.

What drugs are being tested in NCT03863132?

Interventions in NCT03863132: TAVR.

What condition does NCT03863132 study?

NCT03863132 studies Aortic Valve Stenosis.

Is NCT03863132 still recruiting?

NCT03863132 is currently active, enrolled. Last updated 4 May 2025.

Last reviewed 2025-05-04 · How we verify

NCT03863132: REBOOT-PARADOX

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

accuRate Evaluation of Benefit With Optimal Medical Treatment With or Without Transcatheter Valve Repair of PARADOXical Low Flow Low Gradient Aortic Stenosis

Active, enrolled NA Last updated 4 May 2025

What this trial tests

NA trial testing TAVR in Aortic Valve Stenosis in 120 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

3 July 2019

Primary endpoint
1 September 2027

1 March 2028

Quick facts

Lead sponsor	IHF GmbH - Institut für Herzinfarktforschung
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	3 July 2019
Primary completion	1 September 2027
Estimated completion	1 March 2028
Sites	1 location across Germany

Drugs / interventions tested

TAVR

Conditions studied

Aortic Valve Stenosis — all drugs for Aortic Valve Stenosis →

Sponsor

IHF GmbH - Institut für Herzinfarktforschung — full company profile →

Who can join

18 and older, any sex, with Aortic Valve Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aim of this study is to evaluate whether microsurgical repair or replacement of the aortic valve is a treatment option for a subgroup of patients suffering from aortic Stenosis.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

TAVI in patients with low-flow low-gradient aortic stenosis-short-term and long-term outcomes.
Steffen J, Reißig N, Andreae D, Beckmann M, et al · · 2022 · cited 23× · PMID 35320407 · DOI 10.1007/s00392-022-02011-4
Right ventricular dysfunction and impaired right ventricular-pulmonary arterial coupling in paradoxical low-flow, low-gradient aortic stenosis.
Nies RJ, Nettersheim FS, Braumann S, Ney S, et al · · 2024 · cited 5× · PMID 38887164 · DOI 10.1002/ejhf.3329

Verify or expand the search:

Other trials of TAVR

Trials testing the same drug.

NCT04678934 — Cerebral Lesion and Neurocognitive Status Changes After TAVR · unknown
NCT04347603 — Sedation or General Anesthesia During TAVR · NA · completed
NCT04734392 — Reducing Pacemaker Implantation After TAVR With Modified Implantation Technique · completed
NCT05721820 — Aortic Cross-clamp and Opening After Transcatheter Aortic Valve Implantation: a Real Issue? · completed
NCT04086836 — Swedish Study on STroke After TAVR · completed

Other recruiting trials for Aortic Valve Stenosis

Currently open trials in the same condition.

NCT07455292 — Phenotyping Left Ventricle Failure With Hemodynamic Biomarkers From 4D Flow Magnetic Resonance Imaging · NA · recruiting
NCT07008911 — CardioHeartConnect: Commercially Available Fitness for Cardiac Rehabilitation · NA · recruiting
NCT07145463 — Prospective, Multicenter, Randomized Controlled Clinical Study Evaluating the VitaFlow Liberty® Flex Transcatheter Aorti · NA · recruiting
NCT07520656 — Impact of Transcatheter Aortic Valve Implantation and Mitral Valve Repair on Sleep-Disordered Breathing · recruiting
NCT07267117 — Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease · recruiting

Other IHF GmbH - Institut für Herzinfarktforschung trials

Trials by the same sponsor.

NCT05717192 — BENTO - Bronchoscopic Lung Volume Reduction in Severe Emphysema Using Thermoablation · NA · recruiting
NCT04612179 — Post-Market Registry to Evaluate the Safety and Efficacy of the The SUPRAFLEX CRUZ™ Sirolimus Eluting Coronary Stent Sys · completed
NCT04611607 — Cangrelor in Patients With Acute Myocardial Infarction Undergoing PCI After CPR, Ventilated or Cardiogenic Shock · completed
NCT04398654 — Pulmonary Artery Sensor System Pressure Monitoring to Improve Heart Failure (HF) Outcomes · NA · active not recruiting
NCT04335188 — COVID-19 Registry Rhineland-Palatinate (Germany) · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03863132 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by IHF GmbH - Institut für Herzinfarktforschung
Last refreshed: 4 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03863132.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing